Since MUC16 (and its fragment CA125) contributes to the evasion of the body’s immune defense against the cancer cells, as well as directly promoting cancer cell growth and spread [3], there have been major efforts to target MUC16 with antibodies (Oregovomab) and/or vaccines (Abagovomab) to better treat ovarian cancer [3]. This evidence concerns the gene MUC16 and ovarian carcinoma.